Dual-target CAR T-cell therapy exhibits ‘profound’ remission in systemic sclerosis

A dual-target CD19/BCMA chimeric antigen receptor T-cell therapy yielded “profound, sustained” remission in 11 patients with refractory systemic sclerosis, according to data presented at the EULAR 2026 Congress.“As we all know, despite advances in immunosuppressive, biologic and antifibrotic therapies, a subset of patients with refractory, progressive systemic sclerosis